Moderna Finalizes Agreement with the Government of the Republic of Kenya to Establish an mRNA Manufacturing Facility

Facility to enable access to manufactured mRNA vaccines for Kenya and the African continent, providing health security and building upon Moderna’s global public health commitments

The facility will be capable of producing up to 500 million doses each year

CAMBRIDGE, MA & NAIROBI, KENYA/ ACCESSWIRE / March 30, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and the Government of the Republic of Kenya have finalized an agreement to establish an mRNA manufacturing facility in the Republic of Kenya. This will be the Company’s first mRNA manufacturing facility in Africa.

In partnership with the Government of the Republic of Kenya, Moderna will build a state-of-the-art mRNA facility in Kenya to produce up to 500 million doses of vaccines each year. The Company expects the new facility to enable drug substance and drug product manufacturing for Kenya and the African continent. In addition, this facility will have surge capacity to rapidly scale and respond to public health emergencies on the continent and around the world.

“The finalization of our agreement with the Government of the Republic of Kenya is a key pillar of our global public health strategy, where we hope to bring mRNA innovation to the people of Africa in areas of high unmet need, such as acute respiratory infections, as well as persistent infectious diseases like HIV and outbreak threats such as Zika and Ebola,” said Stéphane Bancel, Chief Executive Officer of Moderna. “This also demonstrates our confidence in the investment climate in Kenya and the importance of utilizing mRNA technology to build resilience in healthcare security in Africa. We are also grateful for the leadership of the U.S. Ambassador to Kenya, Meg Whitman, and Samantha Power, in her role as Administrator of the United States Agency for International Development for their instrumental support of this project.”

“We are excited about this milestone that brings to bear our efforts as Government to sustain our economic model of facilitating investments that serve not only Kenya but the African continent. My Government commits to supporting this investment as a critical signal to the investment community that Kenya is open for business,” said President William Ruto.

“This investment creates the momentum to meet the $10 billion annual target under the Government’s manufacturing 20 by 30 vision, where we plan to grow the contribution of manufacturing to GDP to 20% by the year 2030 from the current 7%,” said Kenya’s Cabinet Secretary for Investments, Trade, and Industry Hon. Moses Kuria.

The Government of Kenya has championed an accelerated investment agenda to grow foreign direct investment levels from the current levels of $448 million annually to $10 billion annually, making the country’s goal the continent’s most ambitious agenda to attract investments as an enabler to job creation. Moderna’s investment signifies confidence in the business environment in Kenya and readiness to support foreign and local investment in the healthcare sector, as well as Moderna’s ongoing commitment to global public health. Moderna will operate under a Special Economic Zone (SEZ) status, signifying Kenya’s increasing focus on the SEZ program as a key enabler of economic growth.

With this agreement, Moderna has commitments to establish mRNA manufacturing facilities in Kenya, the United States, Canada, Australia, and the United Kingdom, furthering health security around the world. Moderna has spent more than a decade refining its mRNA platform to accelerate the pace and success of mRNA medicines. The speed, scale, and flexibility of Moderna’s mRNA platform is uniquely suited for rapid response to serious international epidemics, commonly referred to as Disease X.[i]

Moderna is committed to advancing into clinical studies a portfolio of 15 vaccine programs targeting emerging or neglected infectious diseases by 2025, advancing vaccines that address current diseases of significant impact to low- and middle-income countries, and those that prepare for Disease X. Moderna will prioritize development efforts against pathogens identified as persistent global health threats, including HIV, tuberculosis (TB) and malaria, neglected tropical diseases and the priority pathogens of the World Health Organization and the Coalition for Epidemic Preparedness Innovations. Learn more at https://www.modernatx.com/responsibility/our-commitment.

About Moderna

In over 10 years since its inception, Moderna has transformed from a research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio, and integrated manufacturing facilities that allow for rapid clinical and commercial production at scale. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna’s capabilities have come together to allow the authorized use and approval of one of the earliest and most effective vaccines against the COVID pandemic.

Moderna’s mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology, and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past eight years. To learn more, visit www.modernatx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the Company’s plans to build an mRNA manufacturing facility in Kenya; the anticipated capacity and output for that facility; the ability of the facility to respond to public health emergencies; Moderna’s aspiration to develop treatments or vaccines against HIV, Zika, Ebola, and other public health pathogens; the ability of Moderna’s mRNA platform to respond to future epidemics; foreign investment in the health sector in Kenya; the advantages of doing business in a Kenyan Special Economic Zone; and Moderna’s plans to establish manufacturing facilities in the United State, Canada, United Kingdom, and Australia. In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “could,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading “Risk Factors” in Moderna’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission (SEC), which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date of this press release.

Moderna Contacts:

Media:

Luke Mircea Willats
Senior Director, Corporate Communications
Luke.Mirceawillats@modernatx.com

Investors:

Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com

[i] “Disease X” was named by the WHO to represent the knowledge that a serious international epidemic could be caused by a pathogen currently unknown to cause human disease. https://www.who.int/activities/prioritizing-diseases-for-research-and-development-in-emergency-contexts

SOURCE: Moderna, Inc.

Bodog Launches Casino Operations in Regulated Isle of Man

New Bodog.io casino platform to exclusively accept cryptocurrency payments via Isle of Man license

DOUGLAS, ISLE of MAN / ACCESSWIRE / March 22, 2023 / Leading online casino Bodog today announces that it has acquired an all-new gambling license in the Isle of Man in the wake of launching its new casino-only platform, Bodog.io. Designed exclusively for cryptocurrency wagers, Bodog.io is an excellent option for players seeking fast and secure transactions.

Having been awarded this license from The Isle of Man Gambling Commission, Bodog is now in a position to expand casino operations in more territories under favorable regulation, with a new site, under the same trusted brand name existing since 1994.

“We are thrilled to have secured our license in the Isle of Man ahead of the Bodog.io launch,” said a spokesperson for Bodog. “Our team has worked hard to create a crypto-native online casino that provides players with a safe, secure, and fun gaming experience. We are confident that our players will enjoy the platform as we aim to uphold our commitment to safe and responsible gambling as we do with all our brands.”

The Isle of Man Gambling Supervision Commission (GSC) is known globally for ensuring operators are in full compliance with all regulations and is committed to effective regulatory oversight of the online gambling industry.

Founded in 1994, Bodog has become one of the most widely known online casinos in the industry. With around-the-clock customer service available to players, as well as various features such as crypto wagering and play in mBTC, players from all over the world prefer Bodog as their reliable gaming partner. Under the Bodog.io webpage regulated by Isle of Man and operated by Star Jar (IOM) Ltd, the company’s focus on crypto-exclusive casino games on a user-friendly platform will add to its reputation for cutting-edge projects.

About Bodog

Founded in 1994, Bodog is considered an industry leader, providing players with a world-class, full Vegas-style casino. Bodog’s Customer Service team is available 24/7 and dedicated to making sure sessions go off without a hitch. For more information, please visit bodog.io

Contact:

Kyle Smith
Bodog Communications Director
Email: bodogpress@gmail.com

SOURCE: Bodog

 

Licensed Crypto-Fiat Infrastructure Provider Encryptus Soft Launches in TechHub Kenya

VILNIUS, LITHUANIA / ACCESSWIRE / February 19, 2023 / Encryptus, a licensed and compliant crypto-fiat trading platform, is thrilled to announce its soft entry into the African Continent, starting with Kenya.

Encryptus will mark their exploratory journey in the upcoming Africa Tech Summit in Nairobi, Kenya. As a trailblazer in the crypto industry, Encryptus is dedicated to providing crypto and non-crypto companies its infrastructures for Crypto < > Fiat; including Compliances, Coin Monitoring, Fiat and Crypto Liquidity via API to enable institutions to plug into their ecosystem. The fiat services would only be available via Bank wires to KYCed users only.

Encryptus is licensed as a VASP (Virtual Assets Service Provider) in Lithuania and Licensed as a “Proprietary Trading in Crypto Commodities” trading desk in Dubai, UAE.

Africa Pushing Through to the Global Scale

Africa has been a rapidly growing market for international companies and is attracting many global corporations to the continent, such as Amazon, Google, and Uber. In the crypto ecosystem, Cardano’s founding partners EMURGO and IOG have built a considerable presence in Africa along with CELO Foundation and LBank Exchange.

With the rise of digital assets and cryptocurrencies, regulations for digital assets are becoming increasingly important in Africa. In recent years, there has been a growing demand for cryptocurrencies and digital assets in Africa, leading to a need for regulations to ensure the security and stability of these investments.

The African startup scene has also seen significant rise, with a record $5.4 billion raised in 2022, according to a report by Briter Bridges. Startups in Nigeria, Kenya, South Africa, and Egypt accounted for 75% of all funding in 2022. This highlights the growing potential of the African startup scene and the increasing number of investors who are taking an interest in this market.

Crypto adoption in Africa has also been expanding in recent years. According to Chainalysis, Africa has the fastest-growing crypto market in the world.

Encryptus is well integrated with Industry leaders for self custody, coin monitoring and KYC providers for compliant onboarding. The Institutions can make use to the infrastructure by simply plugging into the Encryptus APIs. Encryptus services are also available on their platform for HNWIs and Institutions who simply want to use their services.

Encryptus will mark their soft launch at one of the largest African Tech event; “Africa Summit in Nairobi”

Encryptus’s Founder & CEO, Shantnoo Saxsena will also be sharing the stage with some industry leaders from Polygon, CELO Foundation and Nestcoin. When asked for comments for why Encryptus chose Africa, Shantnoo replied ” I started my crypto journey with a Kenyan startup in 2016. The Kenyan ecosystem is getting exciting and we have the right infrastructure ranging from Compliance to Fiat and Crypto Liquidity to empower other potential partners to build on top of our ecosystem. Encryptus is in the exploratory stage, but we are committed to bring innovative Crypto < > Fiat on-ramps and off-ramps solutions to the Kenyan ecosystem. The fiat and cryptos must coexist and we will work with the regulators and the banks to build the infrastructure together”

Twitter: https://twitter.com/EncryptusGlobal
LinkedIn: https://www.linkedin.com/company/encryptus/
Website: https://encryptus.io/

Please free to contact Abhi@encryptus.io for any queries.

SOURCE: Encryptus

Agreement with Altima to Produce Cheap & Clean Hydrogen in Alberta & British-Colombia

MONTREAL, QC / ACCESSWIRE / February 14, 2023 / St-Georges Eco-Mining Corp. (CSE:SX)(OTCQB:SXOOF)(FSE:85G1) is pleased to announce that its subsidiary H2SX and Altima Resources Limited (TSX-V: ARH) have entered into an agreement via a binding term sheet to move forward with the production of cheap and clean hydrogen (ccH2™) in Canada.

Altima has expressed its intention to use H2SX’s hydrogen production (ccH2™) and nano-carbon technology for the conversion of natural gas originating from gas & condensate wells in Alberta and British Columbia, Canada. H2SX will partner and will work on an exclusive basis with Altima in British Columbia and Alberta in the natural gas domain and for projects and companies that have traditional natural gas production of 65 MMcf/d or less.

In accordance with the provisions of the Terms (ccH2™) Altima will issue to H2SX 6,000,000 common shares upon the completion of milestones as set out in the performance shares schedule (the “Performance Shares“) below:

  • 2,000,000 shares to be issued upon delivery of a preliminary technological engineering report.
  • 2,000,000 shares to be issued upon receipt of a detailed engineering report tailored to Altima’s initial project.
  • 2,000,000 shares upon the delivery of a Preliminary Economical Assessment or a Prefeasibility Study.

These shares will be subject to such further restrictions on resale as may apply under applicable securities laws. The close of the issuance of shares is subject to further review and acceptance by the TSX Venture Exchange.

In addition to the issuance of Performance Shares, Altima has committed to the construction of a hydrogen processing facility utilizing the patented technology. Altima will fund and be co-operator of the hydrogen production plant(s) in relation to the gas wells it currently operates and in the future. One hundred percent of all capital expenditures will be reimbursed to Altima prior to any profit sharing between the joint venture parties.

Altima will be responsible to provide and manage the natural gas input into the joint venture operations and all infrastructures and logistics associated with it and will receive credits for the sale of hydrocarbons to the green hydrogen operation through this producing joint venture.

H2SX and its partner will be entitled to receive a 5% NRR for which a long form royalty agreement (the “Royalty Agreement“) will be executed and will be an integral part of the Joint Venture Agreement between the parties; A formal management structure for the anticipated joint venture will be put in place between the parties.

“(…) We look forward to working with H2SX in moving this exciting zero greenhouse gas (CO2) emission hydrogen production technology, into commercialization and for other prospective green tech opportunities that could benefit from utilizing low-cost green hydrogen (…)” said Joe DeVries, President & CEO of Altima Resources.

“(…) Alberta and British Columbia are strategic locations for H2SX. They will benefit from our low-cost, zero greenhouse gas (CO2) emission hydrogen production technology just as we will benefit from the low costs of their natural gas. A perfect synergy between Altima and us for the benefit of all. The production of cheap and clean hydrogen will spark a multitude of other opportunities such as the production of methanol, ammonia, or fertilizers (urea) with a very low environmental footprint. We can only be excited to start this collaboration with Altima as soon as possible (…,)” said Sabin Boily, CEO of H2SX.

________________________________________________________________________________________________________________________

ON BEHALF OF THE BOARD OF DIRECTORS

“Frank Dumas”

FRANK DUMAS

Director & COO

About St-Georges Eco-Mining Corp.

St-Georges develops new technologies to solve some of the most common environmental problems in the mining sector, including maximizing metal recovery and full circle EV battery recycling. The Company explores for nickel & PGEs on the Julie Nickel Project and the Manicougan Palladium Project on Quebec’s North Shore and has multiple exploration projects in Iceland, including the Thor Gold Project. Headquartered in Montreal, St-Georges’ stock is listed on the CSE under the symbol SX and trades on the Frankfurt Stock Exchange under the symbol 85G1 and on the OTCQB Venture Market for early stage and developing U.S. and international companies under the symbol SXOOF. Companies are current in their reporting and undergo an annual verification and management certification process. Investors can find Real-Time quotes and market information for the company on www.otcmarkets.com

The Canadian Securities Exchange (CSE) has not reviewed and does not accept responsibility for the adequacy or the accuracy of the contents of this release.

SOURCE: St-Georges Eco-Mining Corp.